Mead Johnson Nutrition Company

Nederlandse Organisatie Voor Toegepast-natuurwetenschappelijk Onderzoek Tno

Robert Kleemann

Peter Ydo Wielinga

Teartse Tim Lambers

Gabriele Gross

Eric A F Van Tol

Marieke H Schoemaker

Johan Hendrikus Verheijen

Reinout Stoop

Teake Kooistra

The present disclosure relates to nutritional supplement including a peptide component. The nutritional supplement further includes a source of long-chain polyunsaturated fatty acids andGG. The disclosure further relates to methods of protecting against obesity and its related metabolic disorders and inflammatory diseases in a target subject by providing the nutritional supplement(s) disclosed herein to a target subject, which includes a pediatric subject.

Nutritional supplements containing a peptide component and uses thereof

The invention relates to the surprising find that low density lipoprotein receptor-deficient mice (LDLr) mice when fed with high energy diets produce controllable and consistent diabetic complications, especially renal damage, similar to the human pathophysiology and biological response. The invention thus comprises a method for discovering a preventive or therapeutic regimen for the prevention or treatment of diabetic micro- or macrovascular complications, comprising the steps of: Specifically in such a method renal damage is assessed. Also use of said mice fed with a high energy diet for studying the diabetic micro- and macrovascular complications is part of the invention.

Animal model for non alcoholic steato hepatitis and liver fibrosis

The invention relates to the surprising find that low density lipoprotein receptor-deficient mice (LDLr&#x2212;/&#x2212;) mice when fed with high energy diets produce controllable and consistent diabetic complications, especially renal damage, similar to the human pathophysiology and biological response. The invention thus comprises a method for discovering a preventive or therapeutic regimen for the prevention or treatment of diabetic micro- or macrovascular complications, comprising the steps of: a. feeding LDLr&#x2212;/&#x2212; mice, which have not been treated with streptozotocin, with a high energy diet; b. before, during and/or after this diet treating the mice with the preventive or therapeutic regimen; c. checking whether any change in the micro- or macrovascular system of the animal occurs. Specifically in such a method renal damage is assessed. Also use of said mice fed with a high energy diet for studying the diabetic micro- and macrovascular complications is part of the invention.

Animal model for diabetic complications

Growing community of inventors

Delft, Netherlands

Robert Kleemann